Schering AG. / Novartis / Applied BioSciences / Merck Research Laboratories / 3M / Epo / Danishefsky / John Wiley & Sons Inc. / Nicolaou / Sloan-Kettering / Bristol-Myers Squibb / /
Country
Switzerland / Germany / /
Event
Product Issues / /
Facility
Institute of Pharmaceutical Sciences / Swiss Federal Institute of Technology / Sloan-Kettering Cancer Center / Horwitz laboratory / /
IndustryTerm
chemical synthesis / natural product / clinical applications / cancer therapy / natural products / heterologous expression systems / Treatment of human cancer / treatment of a variety of cancer / taxane-binding site / cell-free in vitro systems / lactone-based natural products / shared binding site / microtubule network / favorable biopharmaceutical properties / /
MedicalCondition
human breast carcinoma / solid human tumors / multidrug-resistant tumors / LS174T human colon carcinomas / solid tumors / Taxol-resistant tumors / carcinoma / Taxolsensitive tumor / A2780Tax human ovarian carcinomas / ovarian tumors / non-small cell lung cancer / drug-sensitive human cancer / HCT116 colon carcinoma / multidrug-resistant human tumor / A549 lung carcinoma / breast carcinoma / human T-cell acute leukemia / human anaplastic thyroid carcinoma / tumor / INTRODUCTION Cancer / significant tumor / cancer / human leukemia / tumors / NSCLC / human ovarian carcinoma / several drug-sensitive human tumor / human cancer / murine sarcoma / stable disease / Taxol-resistant tumor / epidermoid carcinoma / /
MedicalTreatment
chemotherapy / cancer therapy / /
Organization
Institute of Pharmaceutical Sciences / Swiss Federal Institute of Technology / Sloan-Kettering Cancer Center / U.S. Food and Drug Administration / DISCOVERY OF IMPROVED MICROTUBULE INHIBITORS KARL-HEINZ ALTMANN Department of Chemistry and Applied BioSciences / /
1 THE CHEMISTRY AND BIOLOGY OF EPOTHILONES—LEAD STRUCTURES FOR THE DISCOVERY OF IMPROVED MICROTUBULE INHIBITORS KARL-HEINZ ALTMANN